Jul 31, 2024 / 11:30PM GMT
Christian Behrenbruch - Telix Pharmaceuticals Ltd - Group Chief Executive Officer, Managing Director, Executive Director
Thanks very much. Good morning, colleagues and shareholders. Thanks for joining the Telix management team on this investor call and for the opportunity to clarify the events in the last 24 hours, specifically the FDA's issuance of a refusal to file notice for the TLX250-CDx program, our renal cancer PET imaging agent.
Whenever we experience a setback in our programs, we always believe it's important to be front-footed and transparent. Today is no exception. I'm joined on the call by Kyahn Williamson, SVP of Investor Relations; and Darren Smith, Group CFO, and they are available to help answer questions at the end of this call, if need be.
Our goal for this call is to provide a little more color around what has happened and why it has impacted time lines, what remediation is involved and to assure shareholders and other key stakeholders that this is a relatively minor issue. However, it goes without saying we also share your frustration. Drug development is challenging,
Telix Pharmaceuticals Ltd Investor Conference Call Transcript
Aug 01, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers